{
  "drug_name": "Telithromycin",
  "tradename": "Ketek",
  "usage_and_dosing": {
    "general": [
      "Telithromycin is a ketolide antibiotic (similar to macrolides) used for treatment of mild to moderate community-acquired pneumonia (CAP). Telithromycin is active against multi-drug resistant strains of Strep. pneumoniae.",
      "Contraindicated in myasthenia gravis. Other antibiotics that may unmask or exacerbate myasthenia gravis: aminoglycosides, polymyxins, fluoroquinolones.",
      "May cause fatal hepatotoxicity.",
      "Blurred vision due to slow accommodation.",
      "Hepatic, vision, and myasthenic complications may be due to inhibition of nicotinic acetylcholine receptors at neuromuscular junctions; Antimicrob Ag Chemother 54:5399, 2010."
    ],
    "adult_dose": {
      "community_acquired_pneumonia": "800 mg po once daily x 7-10 days"
    },
    "pediatric_dose": {
      "dose_age_gt_28_days": "Safety and efficacy not established",
      "max_day": "-"
    }
  },
  "renal_adjustment": {
    "notes": [
        "Body weight and Creatinine Clearance calculations",
        "CrCl = Creatinine clearance (mL/min)",
        "CAPD = Continuous Ambulatory Peritoneal Dialysis",
        "CRRT = Continuous Renal Replacement Therapy",
        "AD = after hemodialysis",
        "SLED = sustained low efficiency dialysis",
        "Dosage adjustment may be required in hepatic disease."
    ],
    "half_life_normal": "10",
    "half_life_esrd": "15",
    "dose_normal_function": "800 mg po q24h",
    "crcl_or_egfr": "CrCl ≥30: No dosage adjustment. CrCl <30: 600 mg q24h",
    "hemodialysis": "600 mg q24h (give AD on dialysis days)",
    "capd": "No data",
    "crrt": "No data",
    "sled": "No data"
  },
  "hepatic_adjustment": {
    "note": "Reduce dose to 400 mg q24h in patients with CrCl <30 mL/min plus coexisting hepatic impairment.",
    "mild_impairment_child_pugh_a": "No dosage adjustment",
    "moderate_impairment_child_pugh_b": "No dosage adjustment",
    "severe_impairment_child_pugh_c": "No dosage adjustment"
  },
  "adverse_effects": [
    "2 cases acute liver failure and 23 cases serious liver injury reported, or 23 cases per 10 million prescriptions. Occurred during or immediately after treatment (Ann Intern Med 144:415, 2006; Ann Intern Med 144:447, 2006).",
    "Uncommon: blurred vision 2° to slow accommodation; may cause exacerbation of myasthenia gravis (Black Box Warning). Potential QTc prolongation. Several drug-drug interactions, N Engl J Med 355:2260, 2006.",
    "Nausea (7%), vomiting (2%), diarrhea (10%), C. difficile colitis, hepatic failure, headache (2%).",
    "Transient loss of consciousness has been reported; avoid hazardous activities.",
    "Potential for QTc prolongation and drug interactions."
  ],
  "pregnancy_risk": {
    "fda_risk_category": "C",
    "lactation": "Probably safe with monitoring, but no data available; avoid if possible.",
    "footnote": "Capital letter = Old FDA risk category; Text = New FDA risk category"
  },
  "antimicrobial_spectrum": {
    "preferred": [],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "24-hr AUC/MIC",
    "preparations": "Tab (300, 400 mg)",
    "food_recommendation": "Tab ± food",
    "oral_absorption_percent": "57",
    "tmax_hr": "1",
    "peak_serum_conc_ug_ml": "2.3 (800 mg q24h, SS)",
    "peak_urine_conc_ug_ml": "No data",
    "protein_binding_percent": "60-70",
    "volume_of_distribution_vd_l_kg": "2.9 L/kg",
    "avg_serum_half_life_hr": "10",
    "elimination": "Metabolized, biliary, renal",
    "bile_penetration_percent": "7",
    "csf_blood_percent": "No data",
    "therapeutic_levels_in_csf": "No data",
    "auc_ug_hr_ml": "12.5 (800 mg q24h, 0-24h)"
  },
  "enzyme_interactions": {
    "cyp450_substrate": [],
    "transporter_substrate": [],
    "ugt_substrate": [],
    "cyp450_inhibited": ["CYP3A4"],
    "transporters_inhibited": ["PGP (?)"],
    "ugts_inhibited": [],
    "cyp450_induced": [],
    "transporters_induced": [],
    "ugts_induced": [],
    "serum_drug_concentration_impact": "↑"
  },
  "major_drug_interactions": [
    {
      "drug": "Carbamazepine",
      "effect": "↓ telithromycin",
      "management": "Adjust dosage or avoid"
    },
    {
      "drug": "Digoxin",
      "effect": "↑ digoxin",
      "management": "Monitor, adjust dosage"
    },
    {
      "drug": "Eplerenone",
      "effect": "↑ eplerenone",
      "management": "Contraindicated"
    },
    {
      "drug": "Ergot alkaloids",
      "effect": "↑ ergot alkaloid",
      "management": "Avoid co-administration"
    },
    {
      "drug": "Itraconazole",
      "effect": "↑ telithromycin",
      "management": "Adjust dosage or avoid"
    },
    {
      "drug": "Ketoconazole",
      "effect": "↑ telithromycin",
      "management": "Adjust dosage or avoid"
    },
    {
      "drug": "Metoprolol",
      "effect": "↑ metoprolol",
      "management": "Monitor, adjust dosage"
    },
    {
      "drug": "Midazolam",
      "effect": "↑ midazolam",
      "management": "Monitor, adjust dosage"
    },
    {
      "drug": "Phenobarbital",
      "effect": "↓ telithromycin",
      "management": "Adjust dosage or avoid"
    },
    {
      "drug": "Phenytoin",
      "effect": "↓ telithromycin",
      "management": "Adjust dosage or avoid"
    },
    {
      "drug": "Pimozide",
      "effect": "↑ pimozide",
      "management": "Adjust dosage or avoid"
    },
    {
      "drug": "Simvastatin",
      "effect": "↑ simvastatin",
      "management": "Monitor, adjust dosage"
    },
    {
      "drug": "Sotalol",
      "effect": "↓ sotalol",
      "management": "Monitor, adjust dosage"
    },
    {
      "drug": "Theophylline",
      "effect": "↑ theophylline",
      "management": "Monitor, adjust dosage"
    },
    {
      "drug": "Warfarin",
      "effect": "↑ warfarin (↑ INR)",
      "management": "Monitor INR, adjust dosage"
    }
  ],
  "comments": [
    "2007 Safety review led to removal of acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis and use of Medication Guide for prescribing for CABP",
    "No longer marketed in US."
  ]
}
